ID   MOLT-4F
AC   CVCL_2792
SY   MOLT-4f; Molt-4F; MOLT 4F; Molt/4F; MOLT4F; MOLT4f; MOLT-4-F
DR   CLO; CLO_0050994
DR   BioSample; SAMN03472036
DR   cancercelllines; CVCL_2792
DR   ChEMBL-Cells; CHEMBL3307263
DR   ChEMBL-Targets; CHEMBL613515
DR   GEO; GSM827231
DR   JCRB; JCRB0021
DR   LINCS_LDP; LCL-1031
DR   Progenetix; CVCL_2792
DR   PubChem_Cell_line; CVCL_2792
DR   RCB; RCB1936
DR   TKG; TKG 0229
DR   Wikidata; Q54906370
RX   PubMed=62390;
RX   PubMed=3495441;
RX   PubMed=3518877;
RX   PubMed=6600440;
RX   PubMed=9290701;
RX   PubMed=9738977;
RX   PubMed=20215515;
RX   PubMed=20519628;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11389; STK11; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000428759; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): RCB=RCB1936; TKG=TKG 0229
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 12,13
ST   D16S539: 11,12,13
ST   D5S818: 11,12,13 (RCB=RCB1936)
ST   D5S818: 12,13 (TKG=TKG 0229)
ST   D7S820: 7,8,10 (RCB=RCB1936)
ST   D7S820: 7,8,10,11 (TKG=TKG 0229)
ST   TH01: 6,8
ST   TPOX: 8
ST   vWA: 17,18 (TKG=TKG 0229)
ST   vWA: 17,18,19 (RCB=RCB1936)
DI   NCIt; C9142; Adult T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0013 ! MOLT-4
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 32
//
RX   PubMed=62390; DOI=10.1111/j.1365-3083.1976.tb03029.x;
RA   Yount W.J., Utsinger P.D., Hutt L.M., Buchanan P.D., Korn J.H.,
RA   Fuller C.R., Logue M., Pagano J.S.;
RT   "Subpopulations of human lymphoblastoid cell lines. Correlation with
RT   the expression of surface receptors and content of Epstein-Barr virus
RT   genome.";
RL   Scand. J. Immunol. 5:795-810(1976).
//
RX   PubMed=3495441; DOI=10.1002/eji.1830170503;
RA   Kanowith-Klein S., Saxon A., Uittenbogaart C.H.;
RT   "Constitutive production of B cell differentiation factor-like
RT   activity by human T and B cell lines.";
RL   Eur. J. Immunol. 17:593-598(1987).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6600440; DOI=10.1007/BF02617996;
RA   Uittenbogaart C.H., Cantor Y., Fahey J.L.;
RT   "Growth of human malignant lymphoid cell lines in serum-free medium.";
RL   In Vitro 19:67-72(1983).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x; PMCID=PMC5921886;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20519628; DOI=10.1182/blood-2009-09-244673;
RA   Hirose K., Inukai T., Kikuchi J., Furukawa Y., Ikawa T., Kawamoto H.,
RA   Oram S.H., Gottgens B., Kiyokawa N., Miyagawa Y., Okita H.,
RA   Akahane K., Zhang X.-C., Kuroda I., Honna H., Kagami K., Goi K.,
RA   Kurosawa H., Look A.T., Matsui H., Inaba T., Sugita K.;
RT   "Aberrant induction of LMO2 by the E2A-HLF chimeric transcription
RT   factor and its implication in leukemogenesis of B-precursor ALL with
RT   t(17;19).";
RL   Blood 116:962-970(2010).
//